Clinical-stage biotech company Evaxion A/S (EVAX) is preparing to deliver one of its most consequential clinical updates to date, as the company confirms that all patients in its Phase 2 trial for EVX-01 have completed treatment. The full two-year efficacy data will be presented during an oral session at the ESMO Congress in October 2025, marking a pivotal moment for its AI-Immunology platform and its personalized cancer vaccine strategy.
EVX-01 is designed to generate patient-specific neoantigen vaccines using proprietary algorithms, aiming to trigger targeted immune responses with minimal off-target effects.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com